Empirical Finance’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.75M | Buy |
197,099
+6,618
| +3% | +$173K | 0.2% | 95 |
|
|
2026
Q1 | $5.35M | Sell |
190,481
-277
| -0.1% | -$7.38K | 0.25% | 83 |
|
|
2025
Q4 | $4.75M | Sell |
190,758
-8,425
| -4% | -$212K | 0.23% | 87 |
|
|
2025
Q3 | $5.08M | Buy |
199,183
+1,936
| +1% | +$47.8K | 0.24% | 84 |
|
|
2025
Q2 | $4.78M | Buy |
197,247
+1,228
| +0.6% | +$28.6K | 0.25% | 81 |
|
|
2025
Q1 | $4.97M | Buy |
196,019
+2,671
| +1% | +$69.9K | 0.3% | 68 |
|
|
2024
Q4 | $5.13M | Sell |
193,348
-2,602
| -1% | -$70.6K | 0.3% | 64 |
|
|
2024
Q3 | $5.67M | Buy |
195,950
+4,240
| +2% | +$124K | 0.33% | 63 |
|
|
2024
Q2 | $5.36M | Sell |
191,710
-24,691
| -11% | -$680K | 0.34% | 56 |
|
|
2024
Q1 | $6.01M | Buy |
216,401
+6,958
| +3% | +$193K | 0.37% | 54 |
|
|
2023
Q4 | $6.03M | Buy |
209,443
+1,645
| +0.8% | +$49.7K | 0.42% | 45 |
|
|
2023
Q3 | $6.89M | Buy |
207,798
+20,612
| +11% | +$729K | 0.51% | 36 |
|
|
2023
Q2 | $6.87M | Buy |
187,186
+30,633
| +20% | +$1.19M | 0.53% | 35 |
|
|
2023
Q1 | $6.39M | Buy |
156,553
+8,999
| +6% | +$389K | 0.6% | 31 |
|
|
2022
Q4 | $7.56M | Buy |
147,554
+11,464
| +8% | +$550K | 0.78% | 24 |
|
|
2022
Q3 | $5.96M | Buy |
136,090
+22,491
| +20% | +$1.09M | 0.71% | 26 |
|
|
2022
Q2 | $5.96M | Buy |
113,599
+6,058
| +6% | +$309K | 0.76% | 23 |
|
|
2022
Q1 | $5.57M | Buy |
107,541
+11,520
| +12% | +$598K | 0.62% | 27 |
|
|
2021
Q4 | $5.67M | Buy |
96,021
+25,430
| +36% | +$1.26M | 0.67% | 22 |
|
|
2021
Q3 | $3.04M | Buy |
70,591
+3,920
| +6% | +$174K | 0.46% | 34 |
|
|
2021
Q2 | $2.61M | Buy |
66,671
+9,319
| +16% | +$362K | 0.43% | 38 |
|
|
2021
Q1 | $2.11M | Hold |
57,352
| – | – | 0.37% | 66 |
|
|
2020
Q4 | $2.11M | Buy |
57,352
+7,245
| +14% | +$266K | 0.37% | 66 |
|
|
2020
Q3 | $1.75M | Buy |
50,107
+10,668
| +27% | +$374K | 0.37% | 68 |
|
|
2020
Q2 | $1.22M | Buy |
39,439
+4,919
| +14% | +$167K | 0.31% | 91 |
|
|
2020
Q1 | $1.07M | Buy |
34,520
+11,613
| +51% | +$396K | 0.33% | 82 |
|
|
2019
Q4 | $852K | Buy |
22,907
+8,000
| +54% | +$285K | 0.21% | 111 |
|
|
2019
Q3 | $508K | Buy |
14,907
+251
| +2% | +$9.13K | 0.14% | 118 |
|
|
2019
Q2 | $602K | Buy |
14,656
+88
| +0.6% | +$3.49K | 0.17% | 104 |
|
|
2019
Q1 | $587K | Buy |
14,568
+3,390
| +30% | +$136K | 0.15% | 111 |
|
|
2018
Q4 | $463K | Sell |
11,178
-1,034
| -8% | -$42.9K | 0.14% | 105 |
|
|
2018
Q3 | $511K | Buy |
12,212
+1,339
| +12% | +$51.5K | 0.13% | 98 |
|
|
2018
Q2 | $374K | Sell |
10,873
-3,695
| -25% | -$126K | 0.09% | 95 |
|
|
2018
Q1 | $587K | Buy |
+14,568
| New | +$501K | 0.15% | 111 |
|
|
2017
Q4 | – | Sell |
-6,735
| Closed | -$229K | – | 139 |
|
|
2017
Q3 | $229K | Hold |
6,735
| – | – | 0.08% | 125 |
|
|
2017
Q2 | $215K | Buy |
+6,735
| New | +$212K | 0.08% | 115 |
|
|
2017
Q1 | – | Sell |
-2,968
| Closed | -$92K | – | 442 |
|
|
2016
Q4 | $92K | Buy |
+2,968
| New | +$90.6K | 0.06% | 88 |
|
Other funds holding PFE
Empirical Finance's PFE Position: Q2 2026 in Review
Empirical Finance increased its Pfizer (PFE) stake by 3.5% in Q2 2026, buying an estimated $173K and bringing the position to 197,099 shares worth $4.75M. The position accounts for 0.2% of the portfolio, ranked #95.
Empirical Finance first reported a position in PFE in Q4 2016 and has held it in 37 quarters since. The position peaked at $7.56M in Q4 2022. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Empirical Finance held 197,099 shares of Pfizer worth $4.75M as of Q2 2026.
- Empirical Finance bought 6,618 Pfizer shares in Q2 2026, an estimated $173K.
- Pfizer made up 0.2% of Empirical Finance's portfolio in Q2 2026, its #95 holding.
- Empirical Finance first reported a position in Pfizer in Q4 2016 and has held it in 37 quarters since.
- Empirical Finance's Pfizer position peaked at $7.56M in Q4 2022.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Empirical Finance's 13F filing for Q2 2026, filed 14 Aug 2026.